Currently, the ATR inhibitors M6620, AZD6738, BAY1895344, and VE-821 have been shown to increase lethality of cancer cell lines ATM, defective such as gastric cancer, non-small cell lung cancer and chronic lymphocytic leukemia, strongly suggesting a synthetic lethality interaction between the ATM and ATR pathways [117,118] (Table 1). Here, ATM is linked to B-cell chronic lymphocytic leukemia.